Navigation Links
Westaim announces 2008 first quarter results
Date:5/12/2008

CALGARY, May 12 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the first quarter ended March 31, 2008, it recorded a net loss of $6.9 million or 7 cents per share, on revenues of $5.2 million. In the same quarter last year, the company recorded a net loss of $6.7 million, or 7 cents per share, on revenues of $6.1 million.

Income from continuing operations was $3.2 million for the quarter compared to $1.9 million in the same period last year. The results include a loss from discontinued operations of $10.1 million, primarily reflecting a write-down of capital assets of $7.1 million and severance costs of $2.0 million at the Company's wholly owned subsidiary, iFire Technology Ltd., compared to a loss from discontinued operations of $8.6 million for the first quarter of 2007. The first quarter 2008 results also include a dilution gain of $6.0 million relating to the sale of a non-core wholly owned subsidiary, compared to a dilution gain of $4.5 million in the first quarter of 2007.

At March 31, 2008, Westaim had $38.2 million in consolidated cash and cash equivalents compared to $31.0 million at December 31, 2007. Westaim's cash position, excluding cash and cash equivalents held by its 74.5 per cent owned affiliate NUCRYST Pharmaceuticals Corp., was $14.2 million. In addition, Westaim held asset-backed commercial paper (ABCP) with an estimated fair value of $6.0 million.

Tomorrow, The Westaim Corporation is holding its Annual Meeting of Shareholders in Toronto, Canada at 10:00 a.m. EDT. The meeting will be webcast live and is available through the company website http://www.westaim.com. An archive of the webcast will be posted following the meeting.

The Westaim Corporation's investments include iFire Technology Ltd., and a 74.5 per cent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS). Westaim's common shares are listed and on The Toronto Stock Exchange under the trading symbol WED.

A more detailed discussion of Westaim's 2008 first quarter results can be found at http://www.westaim.com and http://www.sedar.com.

THE WESTAIM CORPORATION

Financial Highlights

(unaudited)

(thousands of dollars except per share data)

-------------------------------------------------------------------------

Three Months Ended March 31

--------------------------------

Consolidated Statements of Operations 2008 2007

-------------------------------------------------------------------------

Revenue $ 5,209 $ 6,131

Income from continuing operations 3,227 1,899

Net loss (6,857) (6,700)

Net income (loss) per common share -

basic and diluted

Continuing operations 0.03 0.02

Net loss (0.07) (0.07)

Weighted average number of common

shares outstanding (thousands) 94,186 93,992

-------------------------------------------------------------------------

Three Months Ended March 31

--------------------------------

Segmented Information 2008 2007

-------------------------------------------------------------------------

Revenue from continuing operations

Nucryst Pharmaceuticals $ 5,209 $ 6,131

-------------------------------------------------------------------------

-------------------------------------------------------------------------

(Loss) income from continuing operations

Nucryst Pharmaceuticals $ (2,238) $ (2,178)

Other (including corporate costs) 5,465 4,077

-------------------------------------------------------------------------

Income from continuing operations $ 3,227 $ 1,899

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Consolidated Balance Sheets March 31, 2008 December 31, 2007

-------------------------------------------------------------------------

Cash and cash equivalents $ 38,222 $ 30,993

Current assets 50,155 51,561

Other assets 24,605 31,826

Current liabilities 6,482 8,461

Shareholders' equity 50,268 56,371


'/>"/>
SOURCE Westaim Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Westaim Corporation update on status of short-term investments
2. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. Westaim announces 2007 third quarter results
4. Westaim reduces ABCP exposure
5. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
6. Westaim announces 2007 year-end results
7. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that it will soon begin franchising throughout the U.S. starting this spring. Current ... bring the practice of meditation mainstream. Current Meditation will be the first meditation ...
(Date:2/23/2017)... ... February 23, 2017 , ... The ... the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to ... autism spectrum disorder (ASD) to see films in an environment that accommodates their ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first ... will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA ... CEO of the Virginia Mason Health System in Seattle since 2000. In addition to ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Report analyzes the worldwide markets for Endodontic Supplies in US$ ... Canada , Japan , ... Latin America , and Rest of World. ... through 2022. Also, a six-year historic analysis is provided for ... and secondary research. Company profiles are primarily based on public ...
(Date:2/24/2017)... -- ITL Limited, ( ASX : ITD ), une société ... les excellents résultats semestriels clos le 31 décembre 2016 ... complète « Résultats et mise à jour sur la croissance ... Faits marquants ... en hausse de 104 %) Bénéfice par ...
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
Breaking Medicine Technology: